Top

BY Jill Russell, Ph.D.

MD Anderson researchers have identified early genomic events that may lead to malignant transformation. They’ve found that tissue adjacent to tumors that appears to be pathologically normal may harbor cells with mutations that could lead to cancer.

“These findings provide important insights to the earliest changes that lead to malignancy and could help with early detection of cancer or even prevention,” says Paul Scheet, Ph.D....

The distribution along the genome of chromosomal alterations, contrasting the profile of normal-appearing adjacent-to-tumor (NAT) tissues and blood. (Click on image to enlarge.)

BY Scott Merville

Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two drugs individually...

BY Meagan Raeke

The recent outbreak of lung injury and death associated with e-cigarettes and vaping has led to a renewed scrutiny of electronic nicotine...

BY Clayton Boldt, Ph.D.

Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies, there remain many opportunities to improve outcomes for patients with cancer. Some may not benefit from available treatments, and others may have highly aggressive or drug-resistant cancers that require new options.

As part of MD Anderson’s commitment to bring our patients the most effective...

TRACTION leader Tim Heffernan, Ph.D., says the translational research platform’s major themes are “new targets, new mechanisms, new drugs and better predictive platforms” to improve cancer treatment.

BY Sarah Zizinia

Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction...

BY Clayton Boldt, Ph.D.

Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...

BY Meagan Raeke

Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine...

BY Clayton Boldt, Ph.D.

Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...

BY Clayton Boldt, Ph. D.

Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...

BY Clayton Boldt, Ph. D.

Results from two MD Anderson-led clinical trials indicate that targeted therapies led to significant improvements in progression-free survival...